Phase I/II Study of 5-Azacytidine With Ara-C in Patients With Relapsed/Refractory Acute Myelogenous Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)

NCT00569010 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

36

Enrollment

OTHER

Sponsor class

Conditions

Acute Myelogenous Leukemia
Myelodysplastic Syndrome
Leukemia

Interventions

DRUG: Azacitidine
DRUG: Ara-C

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]